A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments

A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments

Background: Lipid pathways have been implicated in the pathogenesis of osteoporosis (OP). Lipid-lowering drugs may be used to prevent and treat OP. However, the causal interpretation of results from traditional observational designs is controversial by confounding. We aimed to investigate the causal...

Full description

Bibliographic Details
Main Authors:	Xiao-Hua Li, Wei-Wei Pang, Yue Zhang, Dan-Yang Liu, Qiao-Rong Yi, Ning Wang, Fu-Rong Zhang, Yun Deng, Xiang-Ding Chen, Jonathan Greenbaum, Hong-Mei Xiao, Hong-Wen Deng, Li-Jun Tan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Pharmacology
Subjects:	osteoporosis Mendelian randomization drug repurposing lipid-lowering drugs bezafibrate and fenofibric acid
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1211302/full

Similar Items

Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
by: Junko Oya, et al.
Published: (2023-11-01)

Effect of low doses of bezafibrate and fenofibrate on liver 2-oxo-glutarate dehydrogenase complex in low-protein diet fed rats
by: Malgorzata Elzbieta Knapik-Czajka
Published: (2015-07-01)

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
by: Akihiro Honda, et al.
Published: (2022-04-01)

Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
by: Kazufumi Dohmen, et al.
Published: (2021-10-01)

Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy
by: Juliana Geraix, et al.

Novel Inhibitory Role of Fenofibric Acid by Targeting Cryptic Site on the RBD of SARS-CoV-2
by: Jianxiang Huang, et al.
Published: (2023-02-01)

Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice
by: Andras Franko, et al.
Published: (2022-03-01)

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro
by: Qing-Qing Duan, et al.
Published: (2024-03-01)

Study of the effect of bezafibrate with ginkgo biloba extracts in an animal model of hepatotoxicity induced by doxorubicin
by: Zhwan Azad Abdalla, et al.
Published: (2023-12-01)

Metabolic effects of bezafibrate in mitochondrial disease
by: Hannah Steele, et al.
Published: (2020-03-01)

Systematic identification of risk factors and drug repurposing options for Alzheimer's disease
by: Chong Wu, et al.
Published: (2021-01-01)

Fenofibrate-Induced Lichenoid Drug Eruption: A Rare Culprit
by: Fayeza Mohammed, et al.
Published: (2017-11-01)

Mendelian randomization analysis identifies druggable genes and drugs repurposing for chronic obstructive pulmonary disease
by: Zihui Wang, et al.
Published: (2024-04-01)

Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery
by: Nadir Abbas, et al.
Published: (2024-01-01)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
by: Piyush Patel, et al.
Published: (2016-01-01)

Evaluation of the Pharmacokinetic Drug–Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers
by: Hae Won Lee, et al.
Published: (2020-09-01)

Genetic insight into the putative causal proteins and druggable targets of osteoporosis: a large-scale proteome-wide mendelian randomization study
by: Zhichong Wu, et al.
Published: (2023-06-01)

Long-Term Fenofibrate Treatment Stimulates the Phenotypic Microevolution of Prostate Cancer Cells In Vitro
by: Karolina W. Warzecha, et al.
Published: (2022-10-01)

Binding of Bezafibrate to Human Serum Albumin: Insight into the Non-Covalent Interaction of an Emerging Contaminant with Biomacromolecules
by: Jiabin Chen, et al.
Published: (2012-06-01)

Bezafibrate prevents aging in in vitro-matured porcine oocytes
by: Ju-Yeon Kim, et al.
Published: (2021-07-01)

Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel
by: Marcin Luty, et al.
Published: (2019-01-01)

Osteoporosis and sarcopenia-related traits: A bi-directional Mendelian randomization study
by: Chao Liu, et al.
Published: (2022-09-01)

Bezafibrate alleviates diabetes-induced spermatogenesis dysfunction by inhibiting inflammation and oxidative stress
by: Yang Mu, et al.
Published: (2024-03-01)

Myelin Disruption, Neuroinflammation, and Oxidative Stress Induced by Sulfite in the Striatum of Rats Are Mitigated by the pan-PPAR agonist Bezafibrate
by: Nícolas Manzke Glänzel, et al.
Published: (2023-06-01)

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study[S]
by: Mary K. Wojczynski, et al.
Published: (2010-11-01)

Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]
by: Meade Thomas W
Published: (2001-07-01)

Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia
by: Martin Poruba, et al.
Published: (2019-02-01)

Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics
by: Rayan G. Alamri, et al.
Published: (2017-01-01)

Scale-up and optimization of fenofibrate-loaded fibers electrospun by corona-electrospinning
by: E. Bitay, et al.
Published: (2021-04-01)

Coadministration of Compound Danshen dripping pills and bezafibrate has a protective effect against diabetic retinopathy
by: Le Liu, et al.
Published: (2022-10-01)

A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption
by: Hyun-moon Back, et al.
Published: (2018-01-01)

Repurposing antifungal drugs for cancer therapy
by: Ningna Weng, et al.
Published: (2023-06-01)

Comparison of efficacy and safety of fixed dose combination of rosuvastatin and choline fenofibrate to fixed dose combination of rosuvastatin and fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicentre clinical trial in Indian population
by: Hanmant Barkate, et al.
Published: (2018-01-01)

Unlocking the Medicinal Mysteries: Preventing Lacunar Stroke with Drug Repurposing
by: Linjing Zhang, et al.
Published: (2023-12-01)

Efficacy and Safety of Fenofibrate in Patients with Hyperuricemia
by: Irfan Zafar, et al.
Published: (2012-04-01)

Efficacy and Safety of Fenofibrate in Patients with Hyperuricemia
by: Irfan Zafar, et al.
Published: (2012-04-01)

Fenofibrate-induced renal dysfunction, yes or no?
by: Fatemeh Emami, et al.
Published: (2020-01-01)

Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics
by: Dan-Yang Liu, et al.
Published: (2021-04-01)

Copper and bezafibrate cooperate to rescue cytochrome <it>c</it> oxidase deficiency in cells of patients with <it>sco2</it> mutations
by: Casarin Alberto, et al.
Published: (2012-04-01)

Understanding Fenofibrate Release from Bare and Modified Mesoporous Silica Nanoparticles
by: Giorgia Figari, et al.
Published: (2023-05-01)